Samantha Hawkins

A developer lost its bid for a proposed development in Sandy after a board upheld the city's decision that the project didn’t meet city code.

The Salt Lake City-owned Northwest Pipeline Building will be transformed into a mixed-use building with units available for lease by 2025.

As part of its 2025 Medicare Advantage and Part D Final Rule (the Final Rule), the Centers for Medicare & Medicaid Services (CMS) finalized a number of regulatory changes relating to how Medicare Advantage (MA) plans offer supplemental benefits and how they communicate such benefits to plan members. As previewed in the Proposed 2025 Rules

Cities along the Wasatch Front are cutting hurdles so homeowners can offer a housing solution: small rental properties in the backyard.

On July 9, 2024, the Federal Trade Commission (FTC) Office of Policy Planning released an Interim Staff Report titled Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies

Mintz’s Pharmacy Benefits and PBM Contracting Practice is pleased to present the ‘Third Edition: Q2 2024’ of our Mintz IRA Update, a regular publication that delves into developments of the Inflation Reduction Act of 2022 (IRA) and their impact on pharmaceutical supply chain stakeholders.

The passage of the Inflation Reduction Act of 2022 (IRA) marked a significant milestone in Congress’s ongoing efforts to address escalating health care costs. While the IRA aims to rein in government spending on Medicare and to lower point-of-sale prescription drug costs for Medicare beneficiaries, its implementation, and adoption of the redesigned Medicare Part D program has sparked a cascade of consequences for Medicare Part D plan sponsors (“PDPs”), beneficiaries, and manufacturers.

Since our last edition of the Mintz IRA Update, the Medicare Drug Price Negotiation Program (the “Negotiation Program” or “Program”) and related maximum fair price (MFP) negotiation process for each of the 10 high-expenditure Medicare Part D drugs selected for negotiation (the “Selected Drugs”) has gone into full swing. After the Centers for Medicare and Medicaid Services (CMS) sent initial offers to the manufacturers participating in the first cycle of the Negotiation Program, the Biden administration confirmed that

Mintz’s PBM practice is pleased to present a 2024 year-to-date PBM Policy and Legislative Update. This edition builds upon prior issues and summarizes activity from January through June that impacts the PBM industry. It specifically highlights federal legislative activity and oversight, state legislation and litigation, and other noteworthy events and trends affecting the PBM industry.

A new development proposal aims to bring additional housing to the Lower Avenues by adding five residential units behind a historic 1950’s fourplex, according to…